WallStSmart
FHTX

Foghorn Therapeutics Inc

NASDAQ: FHTX · HEALTHCARE · BIOTECHNOLOGY

$4.75
-0.21% today

Updated 2026-04-30

Market cap
$311.70M
P/E ratio
—
P/S ratio
10.08x
EPS (TTM)
$-1.18
Dividend yield
—
52W range
$3 – $7
Volume
0.2M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Foghorn Therapeutics Inc (FHTX) Financial statements

SEC filings — annual and quarterly data.

Income statementBalance sheetCash flowProfitability

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$430000.00$1.32M$19.23M$34.16M$22.60M$30.91M
Revenue growth (YoY)———+206.7%+1357.8%+77.6%-33.8%+36.8%
Cost of revenue$379000.00$1.79M$57.72M$7.51M$19228.00$109.69M$3.12M$3.33M
Gross profit$-379000.00$-1.79M$-57.28M$1.32M$19.21M$34.16M$22.60M$27.58M
Gross margin——-13322.1%100.0%99.9%100.0%100.0%89.2%
R&D$21.23M$44.36M$57.72M$80.33M$105.62M$109.69M$94.53M$85.47M
SG&A$4.82M$6.72M$11.25M$21.73M$30.75M$32.37M$28.36M$27.55M
Operating income$-26.05M$-51.08M$-68.53M$-100.73M$-117.14M$-107.91M$-102.68M$-82.11M
Operating margin——-15937.4%-7637.1%-609.2%-315.9%-454.3%-265.6%
EBITDA$-25.59M$-48.80M$-67.20M$-96.19M$-113.82M$-104.45M$-97.17M$-78.78M
EBITDA margin——-15628.8%-7292.4%-591.9%-305.8%-429.9%-254.9%
EBIT$-25.97M$-50.59M$-68.53M$-99.41M$-117.14M$-107.91M$-100.28M$-82.11M
Interest expense$371000.00$540000.00$979000.00$1.91M$11.57M———
Income tax————————
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-26.34M$-51.13M$-68.80M$-101.32M$-108.87M$-98.43M$-86.62M$-74.28M
Net income growth (YoY)—-94.1%-34.6%-47.3%-7.5%+9.6%+12.0%+14.2%
Profit margin——-16000.0%-7681.6%-566.2%-288.2%-383.2%-240.3%